AZCOMVI
LIVE

Serial Number

79420542

Owner

TAIHO PHARMACEUTICAL CO., LTD.

Attorney

Norm J. Rich

Filing Date

Feb 21, 2025

Add to watchlist:

No watchlists yet
View on USPTO

AZCOMVI Trademark

Serial Number: 79420542 • Registration: 8122627

AZCOMVI is a trademark filed by TAIHO PHARMACEUTICAL CO., LTD. on February 21, 2025. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

TAIHO PHARMACEUTICAL CO., LTD. (107 trademarks)

CHIYODA-KU, TOKYO , JP

Entity Type: 03

Trademark Details

Filing Date

February 21, 2025

Registration Date

February 3, 2026

Published for Opposition

December 16, 2025

Goods & Services

Pharmaceutical preparations for the treatment of tumor; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; tumor suppressing agents; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders; pharmaceutical preparations for the treatment of muscular diseases and disorders; pharmaceutical preparations for the treatment of urological diseases and disorders; pharmaceutical preparations for the treatment of digestive diseases and disorders; pharmaceutical preparations for the treatment of gastroesophageal reflux diseases and disorders; pharmaceutical preparations for the treatment of hepatic diseases and disorders; pharmaceutical preparations for the treatment of renal diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; immunomodulators and immunosuppressive agents being pharmaceutical preparations for the treatment of immune diseases and disorders; pharmaceutical preparations for the treatment of diseases of the central and peripheral nervous system; pharmaceutical preparations for the treatment of rheumatoid arthritis; pharmaceutical preparations for the treatment of diseases of the blood; pharmaceutical preparations for treating hematological disorders; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for use in chemotherapy; anti-emetic medicines being anti-emetic preparations; pharmaceutical preparations for the treatment of pain; analgesic preparations; antiphlogistic preparations; chemical reagents for medical purposes in the field of oncology

Filing History

NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
Jun 9, 2026 NURC
CORRECTION UNDER SECTION 7 - PROCESSED
May 20, 2026 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 18, 2026 APRE
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 3, 2026 FICR
TEAS SECTION 7 REQUEST RECEIVED
Feb 17, 2026 ES7R
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 3, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 3, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 16, 2025 NPUB
PUBLISHED FOR OPPOSITION
Dec 16, 2025 PUBO
NOTIFICATION PROCESSED BY IB
Dec 11, 2025 GPNX
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 10, 2025 NONP
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 26, 2025 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 25, 2025 OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 25, 2025 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 15, 2025 CNSA
REFUSAL PROCESSED BY IB
Oct 18, 2025 RFNT
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 14, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 14, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 14, 2025 TROA
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 27, 2025 RFCS
REFUSAL PROCESSED BY MPU
Sep 27, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 16, 2025 RFCR
NON-FINAL ACTION WRITTEN
Aug 15, 2025 CNRT
ASSIGNED TO EXAMINER
Jul 2, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 9, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 9, 2025 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Apr 8, 2025 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 3, 2025 REPR